Hexarelin.
About Hexarelin
Hexarelin is among the peptides researched in the context of the growth hormone (GH) axis. In addition to ghrelin receptor activation, hexarelin is described as having an additional pituitary-independent binding partner in cardiac tissue (CD36).
Research Application
Studied in GH-axis research as a more potent successor peptide to GHRP-6. The additionally described, pituitary-independent CD36 binding mechanism in cardiac tissue is discussed separately.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.
- Imbimbo BP, et al. Eur J Clin Pharmacol. 1994;46(5):421–425. PMID 7957521
- Bodart V, et al. Circulation Research. 1999;85(9):796–802. PMID 10532947
- Bodart V, et al. Circulation Research. 2002;90(8):844–849. PMID 11988484
- Rahim A, Shalet SM. Growth Horm IGF Res. 1998;8(Suppl A):141–143. PMID 10990150
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about Hexarelin?
We reply personally – via email or Telegram.